Printer Friendly

Quetiapine bests paroxetine in bipolar trial.

BARCELONA -- Quetiapine monotherapy edged out paroxetine monotherapy in a randomized placebo-controlled trial of patients with bipolar disorder.

By 8 weeks, quetiapine (Seroquel)--both 300 and 600 mg/day--reduced mean depression scores significantly more than did paroxetine (Paxil); the 600-mg dose also was associated with a significantly greater incidence of remission at 8 weeks than either the 300-mg dose or paroxetine 20 mg/day, Dr. Allan Young and his colleagues wrote in a poster presented at the annual congress of the European College of Neuropsychopharmacology.

The study randomized 700 patients with bipolar I or II disorder to either quetiapine 300 mg (229), quetiapine 600 mg (232), paroxetine 20 mg (118), or placebo (121).

By week 8, the mean score change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) was significantly better in both quetiapine groups (-16) than in either the paroxetine (-14) or placebo groups (-13).

At that time, far more patients taking quetiapine met the criteria for response than did those taking paroxetine or placebo (67% vs. 53%).

Treatment-emergent side effects were more common among those taking quetiapine 300 or 600 mg than they were among those taking paroxetine.

The study was sponsored by Astra-Zeneca PLC. Dr. Young of the University of British Columbia, Vancouver, is a paid lecturer for the company and has received grants from it as well.
COPYRIGHT 2008 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Adult Psychiatry
Author:Sullivan, Michele G.
Publication:Clinical Psychiatry News
Article Type:Clinical report
Date:Oct 1, 2008
Previous Article:Meta-analysis: long-term therapy is effective.
Next Article:Rebooting the brain for assertiveness.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters